A Study to Compare the NexGen LPS and LPS-Flex Knee Implants
Launched by ZIMMER BIOMET · Sep 29, 2008
Trial Information
Current as of April 27, 2025
Completed
Keywords
ClinConnect Summary
This study will compare the clinical results of the NexGen LPS femoral component with the higher flexion potential of the NexGen LPS-Flex femoral component in all patients with degenerative joint disease that require total knee arthroplasty. The primary variable of interest is postoperative range of motion achieved with the two devices, which are implanted with slightly different surgical techniques in patients who may also be subjected to different rehabilitation programs depending on the device they are assigned.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age, 21-80 years
- • Sex, Males and females will be included
- • BMI less than or equal to 39 and calf-thigh less than or equal to 90 degrees
- • Stable health, the patient would be able to undergo surgery and participate in the follow-up program based on physical examination and medical history.
- • Patient is willing and able to cooperate in follow-up therapy.
- • Patient exhibits preoperative radiographic evidence of joint degeneration consistent with TKA that cannot be treated in non-operative fashion.
- • Patient has stable and functional collateral ligaments.
- • Patient has potential to perform higher than average range of motion activities.
- • Operative side range of motion flexion greater than or equal to 90 degrees.
- • Severe knee pain and disability due to degenerative joint disease.
- • Patient or patient's legal representative has signed the Informed Consent form.
- Exclusion Criteria:
- • Previous history of infection in the affected joint.
- • Previously failed knee endoprosthesis of any kind.
- • Charcot joint disease or other severe neurosensory deficits.
- • Previous patellectomy.
- • Patient is skeletally immature.
- • Grossly insufficient femoral or tibial bone stock.
- • Patient is pregnant.
- • Varus or valgus deformity greater than 20 degrees.
- • Fixed flexion deformity greater than 15 degrees.
- • Previous high tibial osteotomy.
- • Previous femoral osteotomy.
- • Patient is a poor compliance risk - currently treated for ethanol or drug abuse, physical or mental handicap, etc.
- • Loss of musculature or absence of musculoligamentous supporting structures required for adequate soft tissue balance.
About Zimmer Biomet
Zimmer Biomet is a leading global medical technology company specializing in the design, development, and manufacturing of innovative orthopedic and surgical products. With a commitment to enhancing patient outcomes, Zimmer Biomet focuses on advancing musculoskeletal health through a broad range of solutions, including joint reconstruction, surgical instrumentation, and dental implants. The company emphasizes research and development, conducting numerous clinical trials to evaluate the safety and effectiveness of its products, while fostering collaboration with healthcare professionals to address the evolving needs of patients and providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Birmingham, Alabama, United States
Montreal, Quebec, Canada
Philadelphia, Pennsylvania, United States
Decatur, Georgia, United States
Springfield, Illinois, United States
Mooresville, Indiana, United States
Indianapolis, Indiana, United States
Charlotte, North Carolina, United States
Allentown, Pennsylvania, United States
Greenville, South Carolina, United States
Spartanburg, South Carolina, United States
Nashville, Tennessee, United States
Galveston, Texas, United States
Charlottesville, Virginia, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials